公开(公告)号：US20250051462A1

公开(公告)日：2025-02-13

申请号：US18774057

申请日：2024-07-16

Applicant: CSL LIMITED

Inventor： Andrew Donald Nash ,  Arna Elizabeth Andrews ,  Manuel Baca ,  Kirsten Mae Edwards ,  Matthew Philip Hardy ,  Con Panousis ,  Felicity Meredith Dunlop

IPC: C07K16/28 ,  A61K39/00

Abstract: The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor.

公开(公告)号：US20240216467A1

公开(公告)日：2024-07-04

申请号：US18449039

申请日：2023-08-14

Applicant: CSL Limited

Inventor： Craig RAYNER

IPC: A61K38/17 ,  A61K35/14 ,  A61K45/06

CPC classification number: A61K38/1709 ,  A61K35/14 ,  A61K38/17 ,  A61K45/06

Abstract: An apolipoprotein formulation is provided at a fixed dosage that is efficacious in the prophylactic and/or therapeutic treatment of diseases or conditions including, but not limited to cardiovascular disease, acute coronary syndrome, atherosclerosis, unstable angina pectoris, and myocardial infarction. More particularly, the fixed dosage apolipoprotein formulation displays relatively reduced inter-patient variability compared to weight-adjusted dosages. Typically, the apolipoprotein formulation is a reconstituted high density lipoprotein formulation comprising ApoA1, one or more lipids such as phosphatidylcholine, sphingomyelin and/or phosphatidylglycerol and, optionally, a detergent such as cholate at a level that does not induce liver toxicity.

公开(公告)号：US11957731B2

公开(公告)日：2024-04-16

申请号：US17902580

申请日：2022-09-02

Applicant: CSL Limited

Inventor： Yvonne Vucica ,  Gary Lee Warren

IPC: A61K38/17 ,  A61K9/00 ,  A61K9/19 ,  A61K47/10 ,  A61K47/24 ,  A61K47/26 ,  C07K14/775

CPC classification number: A61K38/1709 ,  A61K9/0019 ,  A61K9/19 ,  A61K47/10 ,  A61K47/24 ,  A61K47/26 ,  C07K14/775

Abstract: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.

公开(公告)号：US11840573B2

公开(公告)日：2023-12-12

申请号：US16953499

申请日：2020-11-20

Applicant: CSL LIMITED

Inventor： Catherine Owczarek ,  Con Panousis ,  Nicholas Wilson ,  Matthew Hardy ,  Kirsten Edwards ,  Veronika Rayzman

IPC: C07K16/28 ,  A61P37/06 ,  G01N33/68 ,  A61K39/00

CPC classification number: C07K16/2866 ,  A61P37/06 ,  G01N33/68 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/543 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G01N2333/70596

Abstract: The present disclosure provides a CD131-binding protein comprising an antigen binding domain of an antibody, wherein the antigen binding domain binds to or specifically binds to CD131 and neutralizes signaling by interleukin (IL) 3, IL-5 and granulocyte-macrophage colony stimulating factor (GM-CSF), and uses thereof.

公开(公告)号：US20230142696A1

公开(公告)日：2023-05-11

申请号：US17902580

申请日：2022-09-02

Applicant: CSL Limited

Inventor： Yvonne Vucica ,  Gary Lee Warren

IPC: A61K38/17 ,  A61K47/26 ,  A61K47/10 ,  A61K9/00 ,  A61K9/19 ,  C07K14/775 ,  A61K47/24

CPC classification number: A61K38/1709 ,  A61K47/26 ,  A61K47/10 ,  A61K9/0019 ,  A61K9/19 ,  C07K14/775 ,  A61K47/24

Abstract: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.

公开(公告)号：US11505619B2

公开(公告)日：2022-11-22

申请号：US16772207

申请日：2018-12-14

Applicant: CSL LIMITED

Inventor： Malgorzata Wygrecka ,  Marc Nolte ,  Con Panousis

IPC: C07K16/36 ,  A61K47/60 ,  A61P13/12 ,  A61K38/57

Abstract: The invention relates to an inhibitor of Factor XII (FXII) for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys and/or acute kidney injury, a kit for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys, acute kidney injury, renal fibrosis as a result of rejection of a kidney transplant/allograft, and/or fibrosis of a kidney transplant/allograft as a result of rejection or recurrent underlying disease comprising one inhibitor of Factor XII, and an anti-Factor XII (FXII) antibody or antigen binding fragment thereof for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys and/or acute kidney injury comprising one inhibitor of Factor XII.

公开(公告)号：US11279750B2

公开(公告)日：2022-03-22

申请号：US16575105

申请日：2019-09-18

Applicant: CSL LIMITED

Inventor： Yvonne Vucica ,  Gary Lee Warren

IPC: C07K14/775 ,  C07K1/30 ,  A61K38/17 ,  A61K38/00

Abstract: The present invention relates to processes of obtaining Apo A-1 from an Apo A-1 containing protein fraction (A), comprising suspending—the Apo A-1 containing protein fraction (A) in a buffer solution (B), removing impurities from the suspension while keeping the Apo A-1 proteins solubilized, followed by precipitating Apo A˜I from the suspension and collecting the Apo A-1 precipitate. Apo A-I obtained by such processes, reconstituted HDL obtained from such Apo A-1, and pharmaceutical compositions comprising such Apo A-I and/or reconstituted HDL also are provided.

公开(公告)号：US20210009701A1

公开(公告)日：2021-01-14

申请号：US16924282

申请日：2020-07-09

Applicant: CSL LIMITED

Inventor： Andrew Donald Nash ,  Arna Elizabeth Andrews ,  Manuel Baca ,  Kirsten Mae Edwards ,  Matthew Philip Hardy ,  Con Panousis ,  Felicity Meredith Dunlop

IPC: C07K16/28

Abstract: The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor.

公开(公告)号：US20200038481A1

公开(公告)日：2020-02-06

申请号：US16348106

申请日：2017-11-10

Applicant: CSL LIMITED

Inventor： Samuel Wright ,  Charles Shear ,  Denise D'Andrea ,  Andreas Gille ,  Danielle Duffy

IPC: A61K38/17 ,  A61K9/00 ,  A61K47/26 ,  A61K47/28 ,  A61K31/685 ,  A61K45/06 ,  A61K31/397 ,  A61P9/10 ,  A61P3/06 ,  A61K31/216 ,  A61K31/192 ,  A61K31/366 ,  A61K31/727 ,  A61K31/40 ,  A61K31/505 ,  A61K31/47

Abstract: Reconstituted HDL formulations, methods of treatment comprising same and uses thereof are provided for treating patients after an acute myocardial infarction (MI) event. The reconstituted HDL formulations comprise an apo lipoprotein, a lipid, a detergent and a stabilizer such as sucrose. Treatment of MI patients with repeated infusions of rHDL enhance cholesterol efflux capacity and do not produce significant alterations in liver or kidney function. The MI patient may have normal kidney function or moderate renal impairment.

公开(公告)号：US20190330267A1

公开(公告)日：2019-10-31

申请号：US16455856

申请日：2019-06-28

Applicant: CSL Limited

Inventor： Adam Charlton ,  Mark Napoli ,  Paul Smrdelj ,  Anthony Stowers ,  Vicky Pirzas ,  Magnus Schroeder ,  Ian Walker

IPC: C07K1/18 ,  C07K16/00 ,  C12N9/64 ,  C07K1/22

Abstract: The present invention relates to improved processes for purifying polypeptides of interest by increasing the amount of a polypeptide of interest bound to an ion-exchange matrix relative to the amount of one or more impurities bound to the ion-exchange matrix. This effect is achieved by adding a chemical compound in the process which by also binding to the ion-exchange matrix due to a change that is opposite to the change of the ion-exchange matrix, reduces the binding of impurities more than the binding of the polypeptide of interest.